DelveInsight’s report titled “Invasive Aspergillosis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of invasive aspergillosis, covering historical and projected epidemiology trends along with market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The report delivers detailed insights into the market outlook, treatment landscape, drug uptake, and epidemiological patterns shaping the invasive aspergillosis market over the forecast timeline.
Get a Free sample for the Invasive Aspergillosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/invasive-aspergillosis-market
Key Highlights from the Invasive Aspergillosis Market Report
- The invasive aspergillosis market is projected to grow at a robust CAGR during the study period from 2020 to 2034.
- In March 2024, Astellas Pharma US, Inc. announced that the FDA granted orphan drug designation and pediatric exclusivity to CRESEMBA® (isavuconazonium sulfate) for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric patients. Approved in December 2023, CRESEMBA is indicated as an injectable therapy for children aged one year and older, while its capsule formulation is approved for pediatric patients aged six years and above weighing at least 16 kg.
- DelveInsight estimates that the total prevalent population of aspergillosis across the seven major markets (7MM) reached approximately 1.71 million cases in 2022.
- The diagnosed and treated invasive aspergillosis population in the EU4 and the UK was estimated at around 8,200 patients in 2022, while the total diagnosed and treated population across the 7MM was close to 38,000 cases.
- Leading pipeline candidates expected to enter the market include Olorofim (F2G), Ibrexafungerp (Scynexis), and PC945 (Pulmocide).
Invasive Aspergillosis Overview
Aspergillosis is caused by infection or allergic reactions to the Aspergillus fungus, which is widely present in the environment. The disease manifests in several forms, including Invasive Aspergillosis (IA), Chronic Pulmonary Aspergillosis (CPA), and Allergic Bronchopulmonary Aspergillosis (ABPA), with symptoms varying based on disease type and severity.
Invasive Aspergillosis Epidemiology Insights
The epidemiology section examines historical, current, and forecasted trends from 2020 to 2034 across the 7MM. It evaluates prevalence, severity-based cases, gender distribution, and diagnosed episodic and chronic cases, supported by published studies and expert opinions.
To Know in detail about the Invasive Aspergillosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Invasive Aspergillosis Market Forecast
Invasive Aspergillosis Drug Uptake and Pipeline Development
The report assesses drug adoption rates for marketed and emerging therapies, patient uptake trends, and comparative market share. It also reviews pipeline development activities, highlighting candidates at various stages, along with recent collaborations, mergers, licensing agreements, and other strategic developments.
Key Invasive Aspergillosis Therapies and Companies
Prominent therapies include PC945, Olorofim, Ibrexafungerp, BSG005, Amphotericin B cholesteryl sulfate complex, Posaconazole, and F901318, with key developers such as Pulmocide, F2G Biotech GmbH, Scynexis, Biosergen, CSPC Ouyi Pharmaceutical, and Melbourne Health.
Invasive Aspergillosis Market Strengths and Opportunities
Mid- to late-stage therapies with inhalational, oral, and intravenous routes of administration are expected to improve efficacy, enable faster onset of action, and enhance patient adherence. Growing awareness and limited approved treatment options create strong opportunities for rapid uptake of emerging therapies, including antifungals and immunotherapies.
Overall, the invasive aspergillosis market is set to expand steadily, driven by rising prevalence, improved awareness, and a maturing pipeline of innovative therapies poised to transform future treatment outcomes.
To know more about Invasive Aspergillosis companies working in the treatment market, visit @ Invasive Aspergillosis Clinical Trials and Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
